CIK 0000939767
- Large accelerated filer
EXELIXIS, INC.
Sign in to watch- Ticker
- EXEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jan 1
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 043257395
- Phone
- +1 650-837-7000
- Business address
- 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
- Former names
- EXELIXIS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-04-01 | Lamb Peter EVP, Scientific Strategy & CSO | Exercise or conversion · Option (right to buy) | −60,000 | 0 | ||
| 2021-04-01 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Exercise or conversion | +50,000 | $1.70 | $85K | 663,482 |
| 2021-04-01 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Sale | −50,000 | $23.00 | $1.1M | 613,482 |
| 2021-04-01 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Exercise or conversion · Option (right to buy) | −50,000 | 50,000 | ||
| 2021-03-29 | WYSZOMIERSKI JACK L Director | Exercise or conversion | +40,000 | $3.38 | $135K | 237,809 |
| 2021-03-29 | WYSZOMIERSKI JACK L Director | Sale | −6,220 | $22.64 | $141K | 231,589 |
| 2021-03-29 | WYSZOMIERSKI JACK L Director | Exercise or conversion · Option (right to buy) | −40,000 | 0 | ||
| 2021-03-15 | Garber Alan M Director | Exercise or conversion | +40,000 | $3.38 | $135K | 52,718 |
| 2021-03-15 | Garber Alan M Director | Sale | −40,000 | $23.60 | $944K | 12,718 |
| 2021-03-15 | Garber Alan M Director | Exercise or conversion · Option (right to buy) | −40,000 | 0 | ||
| 2021-03-04 | MORRISSEY MICHAEL President and CEO | Grant or award · Option (right to buy) | +494,700 | 494,700 | ||
| 2021-03-04 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Grant or award | +72,885 | 613,482 | ||
| 2021-03-04 | Hessekiel Jeffrey EVP and General Counsel | Grant or award | +57,135 | 646,248 | ||
| 2021-03-04 | Senner Christopher J. EVP and CFO | Grant or award | +64,150 | 356,591 | ||
| 2021-03-04 | Haley Patrick J. EVP, Commercial | Grant or award | +59,570 | 305,057 | ||
| 2021-03-04 | Lamb Peter EVP, Scientific Strategy & CSO | Grant or award | +49,395 | 389,467 | ||
| 2021-03-01 | Lamb Peter EVP, Scientific Strategy & CSO | Exercise or conversion | +65,000 | $1.70 | $111K | 405,072 |
| 2021-03-01 | Lamb Peter EVP, Scientific Strategy & CSO | Sale | −65,000 | $22.11 | $1.4M | 340,072 |
| 2021-03-01 | Lamb Peter EVP, Scientific Strategy & CSO | Exercise or conversion · Option (right to buy) | −65,000 | 60,000 | ||
| 2021-02-24 | MORRISSEY MICHAEL President and CEO | Gift | −67,374 | 491,813 |
Page 34 of 42 · 836 trades